ELEXACAFTOR | ELEXACAFTOR | ATC R07AX32
RESPIRATORY SYSTEM TREATMENT OF CYSTIC FIBROSIS (CF) THE COMBINED EFFECT OF ELEXACAFTOR, TEZACAFTOR AND IVACAFTOR IS INCREASED QUANTITY AND FUNCTION OF F508DEL-CFTR AT THE CELL SURFACE ELEXACAFTOR AND TEZACAFTOR BIND TO DIFFERENT SITES ON THE CFTR PROTEIN | ORAL | Cmax 14.6 MICROMOLAR Tmax 6 HOUR F 80 PERCENT VD 53.7 LITER PPB 99 PERCENT Cl 1.18 LITER / HOUR HT 29.8 HOUR SOLUBILITY PRACTICALLY INSOLUBLE IN WATER (<1 MG/ML) | CFTR CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | Cystic fibrosis transmembrane conductance regulator P13569 (CFTR_HUMAN) | EMA ANSM (in French) Inxight Drugs Dailymed Drugs.com SIDER side effects Chemical Probes Portal ChEMBL BindingDB DrugBank |